

AcouSort AB Press release
August 10, 2022

AcouSort significantly strengthens its commercial capabilities with the recruitments of Kelley Intehar and Agnes Michanek

AcouSort is rapidly moving towards full commercialization of its solutions for point-of-care diagnostics. In parallel, the company sees a rapidly increasing interest for its technology within precision medicine. With the recruitment of Kelley Intehar as General Manager and Sales Director North America, AcouSort establishes an immediate presence in the US – the world's largest healthcare market. With the recruitment of Agnes Michanek as Commercial Director, AcouSort also enhances the company's corporate commercial function.

Kelley Intehar comes from a position as Commercial Director/North American Sales Specialist at Bio-Techne Corporation. Kelley Intehar has a distinct commercial profile and a unique experience, network, and know-how. At Bio-Techne, Kelley Intehar established an entirely new business area, and she has in-depth knowledge of precision medicine.

Agnes Michanek returns to AcouSort to take up the position as Commercial Director. Agnes Michanek has excellent external communication skills and will drive AcouSort's business development as the company intensifies its commercial efforts with the ambition to accelerate sales of its solutions for point-of-care diagnostics. Agnes was deeply involved in the development of AcouSort's current strategy, which she now will help turn into actions.

"I am absolutely thrilled to welcome Kelley Intehar and Agnes Michanek to the AcouSort team. Kelley has exactly the profile we have been looking for, and she will be instrumental in establishing an AcouSort presence in North America, where we have an opportunity to establish significant sales of our solutions for point-of-care diagnostics. With her in-depth knowledge of precision medicine, Kelley will also contribute to our efforts and ambitions within this area. I would also like to thank our Board Member Katherine Flagg, who was instrumental in the recruitment of Kelley Intehar," says AcouSort CEO Torsten Freltoft.

[For further information about AcouSort, please contact:](#)

Torsten Freltoft, CEO

Phone: +45 2045 0854

Email: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization

strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.